APA (7th ed.) Citation

Butler, M., Weight, R., Haq, R., Javed, A., Chandana, S., Chmielowski, B., . . . Orloff, M. (2024). 1139TiP IDE196 (darovasertib) in combination with crizotinib versus investigator's choice of treatment as first-line therapy in HLA-A2 negative metastatic uveal melanoma. Annals of Oncology, 35, S747. https://doi.org/10.1016/j.annonc.2024.08.2142

Chicago Style (17th ed.) Citation

Butler, M.O, et al. "1139TiP IDE196 (darovasertib) in Combination with Crizotinib Versus Investigator's Choice of Treatment as First-line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma." Annals of Oncology 35 (2024): S747. https://doi.org/10.1016/j.annonc.2024.08.2142.

MLA (9th ed.) Citation

Butler, M.O, et al. "1139TiP IDE196 (darovasertib) in Combination with Crizotinib Versus Investigator's Choice of Treatment as First-line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma." Annals of Oncology, vol. 35, 2024, p. S747, https://doi.org/10.1016/j.annonc.2024.08.2142.